Comparative Drug Ranking for Clinical Decision Support in HIV Treatment



Similar documents
Lessons from the Stanford HIV Drug Resistance Database

Viral Replication. Viral Replication: Basic Concepts

A Platform for Collaborative e-science Applications. Marian Bubak ICS / Cyfronet AGH Krakow, PL bubak@agh.edu.pl

Structure and Function of DNA

Understanding West Nile Virus Infection

Up to $402,000. Insight HIV. Drug Class. 1.2 million people in the United States were living with HIV at the end of 2011 (most recent data).

INSERM/ A. Bernheim. Overcoming clinical relapse in multiple myeloma by understanding and targeting the molecular causes of drug resistance

Cancer Genomics: What Does It Mean for You?

Gene Therapy. The use of DNA as a drug. Edited by Gavin Brooks. BPharm, PhD, MRPharmS (PP) Pharmaceutical Press

Poster # 42 Resistance in PBMCs Can Predict Virological Rebound after Therapy Switch in cart- Treated Patients with Undetectable HIV-RNA

Theonest Ndyetabura KILIMANJARO CHRISTIAN MEDICAL CENTRE / KILIMANJARO CLINICAL RESERCH

Liver Disease and Therapy of Hepatitis B Virus Infections

The Basics of Drug Resistance:

Viral load testing. medical monitoring: viral load testing: 1

RNA Viruses. A Practical Approac h. Alan J. Cann

Chapter 3 South African guidelines and introduction to clinical cases

MicroRNA formation. 4th International Symposium on Non-Surgical Contraceptive Methods of Pet Population Control

Viral Infection: Receptors

Computational Drug Repositioning by Ranking and Integrating Multiple Data Sources

Appendix 2 Molecular Biology Core Curriculum. Websites and Other Resources

Bayesian coalescent inference of population size history

How To Treat Mesothelioma With A Tumor Stem Cell Inhibitor

Genomics and the EHR. Mark Hoffman, Ph.D. Vice President Research Solutions Cerner Corporation

HIV Drug resistanceimplications

Various Viral Vectors Necessary for Gene Therapy Delivery Systems. Abstract

SAP HANA Enabling Genome Analysis

Routine HIV Monitoring

BIG DATA SCIENTIFIC AND COMMERCIAL APPLICATIONS (ITNPD4) LECTURE: DATA SCIENCE IN MEDICINE

Mathematical Analysis of HIV-1 Dynamics in Vivo

MULTIPLE MYELOMA. Dr Malkit S Riyat. MBChB, FRCPath(UK) Consultant Haematologist

The Effects of Cycling on Drug Resistance HIV

BioMmune Technologies Inc. Corporate Presentation 2015

Cancer: Cells Behaving Badly

SYMPOSIUM. June 15, Photonics Center Colloquium Room (906) 8 Saint Mary's St., Boston, MA Boston University

Mid-Clinical Stage Antiviral Drug Development Company

Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents

GROWTH AND DEVELOPMENT

Transcription and Translation of DNA

How To Understand Enzyme Kinetics

ACCESS TO AFFORDABLE TREATMENT FOR HIV/AIDS: THE ISSUES

WHO/HIVRESNET HIV DRUG RESISTANCE LABORATORY STRATEGY

Supplemental Information. McBrayer et al. Supplemental Data

Core Facility Genomics

Core Competencies: HIV/AIDS: HIV Basics HIV/AIDS JEOPARDY* Overview. To change category names: Instructions. 2. Introduce session.

HIV/AIDS Prevention and Care

HCV in 2020: Any cases left? Rafael Esteban Hospital General Universitario Valle Hebron Barcelona. Spain

Chapter 21. What Are HIV and AIDS?

Switch to Dolutegravir plus Rilpivirine dual therapy in cart-experienced Subjects: an Italian cohort

AP BIOLOGY 2009 SCORING GUIDELINES

Activity 7.21 Transcription factors

Medical AI HIV/AIDS Treatment Management System

Methodology Understanding the HIV estimates

A leader in the development and application of information technology to prevent and treat disease.


Electronic Theses and Dissertations UC San Diego

Testing for HIV Drug Resistance

How To Understand Protein-Protein Interaction And Inhibitors

The Body s Defenses CHAPTER 24

ALLIANCE FOR LUPUS RESEARCH AND PFIZER S CENTERS FOR THERAPEUTIC INNOVATION CHALLENGE GRANT PROGRAM PROGRAM GUIDELINES

Reconsideration Code Reconsideration Code Description Nuclear Matrix Protein 22 (NMP22), qualitative

Guidance for Industry Antiviral Product Development Conducting and Submitting Virology Studies to the Agency

Genetics Lecture Notes Lectures 1 2

Chapter 36. Media Directory. Characteristics of Viruses. Primitive Structure of Viruses. Therapy for Viral Infections. Drugs for Viral Infections

What is HIV? What is AIDS? The HIV pandemic HIV transmission Window period Stages of HIV infection

#Aim2Innovate. Share session insights and questions socially. Genomics, Precision Medicine and the EHR 6/17/2015

What is Pharmacogenomics? Personalization of Medications for You! Michigan State Medical Assistants Conference May 6, 2006

Molecular Diagnosis of Hepatitis B and Hepatitis D infections

LEUKEMIA LYMPHOMA MYELOMA Advances in Clinical Trials

Cancer: DNA Synthesis, Mitosis, and Meiosis

Web-Based Genomic Information Integration with Gene Ontology

The Healing Power of Data

Personalized Medicine: Humanity s Ultimate Big Data Challenge. Rob Fassett, MD Chief Medical Informatics Officer Oracle Health Sciences

Recombinant DNA and Biotechnology

Final Review. Aptamers. Making Aptamers: SELEX 6/3/2011. sirna and mirna. Central Dogma. RNAi: A translation regulation mechanism.

Chapter 18: Applications of Immunology

Efficacy of lead-in silibinin and subsequent triple therapy in difficult-to-treat HIV/hepatitis C coinfected patients

A Local Stability of Mathematical Models for Cancer Treatment by Using Gene Therapy

TECHNICAL INSIGHTS TECHNOLOGY ALERT

TTT s : Test and Treat Tracking System on ResearchKit of HIV Carriers in Thailand

Cystic Fibrosis Webquest Sarah Follenweider, The English High School 2009 Summer Research Internship Program

Chapter 20: Antimicrobial Drugs

Chapter 8. Summary and Perspectives

Targeted Therapy What the Surgeon Needs to Know

Transcription:

Comparative Drug Ranking for Clinical Decision Support in HIV Treatment Emiliano Mancini University of Amsterdam 1

Prevalence of HIV 2

Global Overview HIV Infection People living with HIV: 34 million (2010 & 2012) New HIV infections: 2.7 million (2010) - 2.5 (2012) million AIDS- related deaths: 1.8 million (2010) 2.3 (2012) million People receiving Antiretroviral Therapy 6.5 million (2010) 15 million (2015) HIV Treatment Source: UNAIDS 3

P.M.A. Sloot et al., HIV Decision Support: From Molecule to 2 patents and in use in 12 EU Man, Phil. Trans. R. Soc. A, vol. 367, nr 1898 pp. 2691-2703. Hospitals HIV CCR5 CXCR4 Agent-Based Entry Simulation CD4+ Target Cell CA Based Immune Response Phenotype Complex Networks Epidemics Molecular Dynamics Binding Affinity Protein Structure & Binding Affinity Protease and RT mutations DRUG RANKING DECISION SUPPORT Clinical Parameters: -weight - opportunistic infections and tumors -survival Text Mining è Drugranking ç 1 st order logic 4

Complex Interplay in HIV 5

Simulation Results Validation of Dynamics Predictive models CD4+ cells /mm 3 Continuous Therapy CD4+ cells /mm 3 Optimal Therapy CD4 + T 1 0.8 0.6 0.4 CD4+ cells /mm 3 Provirus virion /mm 3 8 weeks on / 4 weeks off CD4+ cells /mm 3 Provirus virion /mm 3 No therapy 0.2 Provirus virion /mm 3 Provirus virion /mm 3 2 4 6 8 10 12 years P.M.A. Sloot et al., 2003, 2005, 2010 E.Mancini et al., 2012 6

HIV Life Cycle 7

HIV RNA virus 10 9 new viruses produced every day RT makes errors during each transcription Due to high error rate, multiple mutations 8

Accumulation of high level resistance Number of Mutations Accumulated 2 mutations 4- fold resistance 3 mutations 10- fold resistance (!) 9

Drug Resistance 250,000 HIV individuals in the USA and Europe with drug resistant viruses. 10% of new infections in USA/Europe occurs with viruses that have at least one drug resistant mutation. Small proportion of patients die because we have no drugs to inhibit their viruses 10

Choosing a HIV therapy Clinicians take informed decisions Yearly Guidelines + Knowledge + Experience that are driven by intuition Clinicians have on average ~5 minutes per patient! 11

How to choose the right therapy? Complex task Short time HIV Genotype and mutations Drugs side effects Drug resistances Drugs interactions Cell counts Errors Consequences Treatment failure à HIV mutations selected More mutations à more treatment failures How to minimize those errors? 12

Drug Resistance Databases HIVdb (Stanford) ANRS (France) REGA (Leuven) Input Output Virus Genotype Level of drug resistance Issue Discordances between them What is the next step? 13

Decision Support System Comparative Drug Ranking System Drug Ranking Component Display Resistances for drugs tailored to individual patients Identifies Discordances between rulesets Literature Mining Component Provides tools to resolve Discordances 14

Comparative Drug Ranking System Drug Ranking Component First order logic to translate and compare rules from different drug ranking rulesets Consistency checks inter and intra rulesets Highlight Discordances 15

Comparative Drug Ranking System Input a viral genome or a set of mutations 16

Drug Ranking Component Alert icon to highlight discordances Display specific rules triggered by input muta,ons Intui,ve visualiza,on of the score Legend of the drug resistance ranking Literature Mining Tool 17

Comparative Drug Ranking System Literature Mining Component Search in PubMed database for relevant papers Extract relations between drugs and specific mutations in analysis Rank papers by relevance to the mutations of the individual patient in analysis 18

Literature Mining Component A novel method 1 to extract and combine causal relations of mutations on HIV drug resistance. Based on Natural Language Processing which produces grammatical relations and applies a set of rules to these relations. Automatically mine > 30.000 PubMed documents and obtain 9,427 causal relations and 3034 sentences with relations Combine the extracted relations using logistic regression and generate resistance values for each <drug, mutation> pair Bui; Ó Nualláin; Boucher, Sloot: Extracting causal relations on HIV drug resistance from literature, BMC Bioinformatics 2010. Bui; S. Katrenko, P.M.A. Sloot: A hybrid approach to extract protein- protein interactions, Bioinformatics 2011. 19

Literature Mining Component 20

Conclusions - 1 Emergence of Drug Resistant mutations Suboptimal treatment à drug resistant mutations Treatment failure HIV mutations selected More treatment failures More mutations Prevent accumulation of high level Drug Resistances 21

Conclusions - 2 Choose the appropriate treatment Display level of resistance for each drug Identify discordances between databases Provide evidence to resolve discordances Clinical Decision Support Deployed on VPH- Share platform 22

Acknowledgements Peter Sloot Fajran Rusadi Piotr Nowakowsky VPH- Share Funded by: European Commission FP7 Contract no: 269978 Thank you! Questions? 23